Genitourinary Cancers

The FDA has recommended that Aveo Oncology should not submit a new drug application for tivozanib with the preliminary overall survival data from the phase III TIVO-3 trial of patients with highly refractory, advanced or metastatic renal cell carcinoma.

Neeraj Agarwal, MD, discusses his preferred sequencing strategies in the treatment of patients with mRCC.

RNA-based analyses of prospectively-collected tumor specimens from patients with metastatic renal cell carcinoma in the phase III COMPARZ trial revealed 4 molecular subgroups, of which a high angiogenesis expression and a low macrophage infiltrate were indicative of response to frontline TKI therapy.

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of Urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses the underutilization of bladder preservation in patients with localized bladder cancer.

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the standard of care in patients with non-muscle invasive bladder cancer (NMIBC).

Peter Clark, MD, professor of medicine and chair of urology, Levine Cancer Institute, Atrium Health, discusses the need for biomarkers in renal cell carcinoma.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the importance of identifying molecular subsets in urothelial cancer.

Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.

Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.

The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the clinical utility of PD-L1 in metastatic renal cell carcinoma (mRCC).

Jonathan L. Wright, MD, MS, FACS, highlights the available therapies for patients with localized muscle-invasive bladder cancer.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

The investigational mitomycin formulation UGN-101 demonstrated a 57% complete response rate in patients with low-grade upper-tract urothelial cancer.

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.